Pharvaris (NASDAQ:PHVS - Get Free Report)'s share price gapped down before the market opened on Wednesday . The stock had previously closed at $22.15, but opened at $21.57. Pharvaris shares last traded at $21.57, with a volume of 792 shares traded.
Analysts Set New Price Targets
Several research firms recently weighed in on PHVS. Morgan Stanley boosted their price target on shares of Pharvaris from $32.00 to $35.00 and gave the stock an "overweight" rating in a report on Thursday, December 7th. Wedbush restated an "outperform" rating and set a $35.00 price target on shares of Pharvaris in a report on Tuesday, March 19th. JMP Securities restated a "market outperform" rating and set a $49.00 price target on shares of Pharvaris in a report on Wednesday, February 14th. Finally, Bank of America lifted their price objective on shares of Pharvaris from $8.00 to $11.00 and gave the stock an "underperform" rating in a research report on Thursday, December 7th.
Read Our Latest Stock Analysis on Pharvaris
Pharvaris Stock Up 0.6 %
The firm has a market cap of $709.71 million, a P/E ratio of -6.92 and a beta of -3.12. The firm's 50-day simple moving average is $26.07 and its 200 day simple moving average is $23.17.
Institutional Trading of Pharvaris
Several hedge funds have recently added to or reduced their stakes in PHVS. Goldman Sachs Group Inc. raised its position in shares of Pharvaris by 2.0% in the second quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company's stock valued at $1,259,000 after purchasing an additional 1,115 shares during the period. Qube Research & Technologies Ltd bought a new stake in shares of Pharvaris in the third quarter valued at approximately $54,000. UBS Group AG bought a new stake in shares of Pharvaris in the fourth quarter valued at approximately $32,000. Tower Research Capital LLC TRC bought a new stake in shares of Pharvaris in the third quarter valued at approximately $26,000. Finally, Bank of America Corp DE raised its position in shares of Pharvaris by 1,054.4% in the first quarter. Bank of America Corp DE now owns 5,772 shares of the company's stock valued at $105,000 after purchasing an additional 5,272 shares during the period.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Featured Articles
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
